Home/Pipeline/MB-106

MB-106

Relapsed/Refractory B-cell NHL & CLL

Phase 1/2Active

Key Facts

Indication
Relapsed/Refractory B-cell NHL & CLL
Phase
Phase 1/2
Status
Active
Company

About Mustang Bio

Mustang Bio is a clinical-stage biopharmaceutical company dedicated to translating breakthroughs in cell therapy into potential cures for cancers with high unmet medical need. Its strategy centers on a capital-efficient model of in-licensing first-in-class candidates, primarily CAR T therapies, from top-tier research institutions like City of Hope. The company has advanced a pipeline of CAR T programs into clinical trials for aggressive brain tumors and hematologic malignancies, with recent Phase 1 data showing promising survival signals. A key pillar of its approach is developing advanced, controlled manufacturing processes to overcome the scalability challenges inherent in cell therapy.

View full company profile

Therapeutic Areas